Evidence map›Paper›PMID 32703874›Full record

ArticleScience (New York, N.Y.)2020

The activities of drug inactive ingredients on biological targets.

Joshua Pottel, Duncan Armstrong, Ling Zou, Alexander Fekete, Xi-Ping Huang, Hayarpi Torosyan, Dallas Bednarczyk, Steven Whitebread, Barun Bhhatarai, Guiqing Liang and 10 more

Open access · greenAbstract read
In one paragraph

Article in Science (New York, N.Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
9.1field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 87 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Antimicrobial cetylpyridinium chloride causes functional inhibition of mitochondria as potently as canonical mitotoxicants, nanostructural disruption of mitochondria, and mitochondrial CaFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2024
    Article
  6. Review
  7. Disassociating drug active ingredients from inactive: ketamine-like synaptic effects of a ketamine excipient.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024
    Article
  8. Article
  9. Pharmaceutical agent cetylpyridinium chloride inhibits immune mast cell function by interfering with calcium mobilization.Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association · 2023
    Article
  10. Review
  11. Article
  12. Transporters in Regulatory Science: Notable Contributions from Dr. Giacomini in the Past Two Decades.Drug metabolism and disposition: the biological fate of chemicals · 2022
    Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Recent advances in drug repurposing using machine learning.Current opinion in chemical biology · 2021
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 7 institutions in 4 countries.

Joshua PottelDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158, USA.ORCID 0000-0002-4455-4713
Duncan ArmstrongPreclinical Safety, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.ORCID 0000-0002-1930-646X
Ling ZouDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158, USA.ORCID 0000-0002-0128-7950
Alexander FeketePreclinical Safety, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.ORCID 0000-0001-9941-9271
Xi-Ping HuangDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC 27759, USA.ORCID 0000-0002-2585-653X
Hayarpi TorosyanDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158, USA.
Dallas BednarczykPK Sciences, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.ORCID 0000-0003-0735-2861
Steven WhitebreadPreclinical Safety, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.ORCID 0000-0001-9295-1396
Barun BhhataraiPK Sciences, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.ORCID 0000-0002-0109-7487
Guiqing LiangPK Sciences, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.
Hong JinPreclinical Safety, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.ORCID 0000-0002-9957-8907
S Nassir GhaemiTranslational Medicine, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA.ORCID 0000-0001-9259-0885
Samuel SlocumDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC 27759, USA.ORCID 0000-0001-5942-4367
Katalin V LukacsNational Heart and Lung Institute, Imperial College, London SW7 2AZ, UK.
John J IrwinDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158, USA.ORCID 0000-0002-1195-6417
Ellen L BergEurofins, DiscoverX, South San Francisco, CA 94080, USA.ORCID 0000-0001-5149-6665
Kathleen M GiacominiDepartment of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94158, USA.ORCID 0000-0001-8041-5430
Bryan L RothDepartment of Pharmacology, University of North Carolina, Chapel Hill, NC 27759, USA.ORCID 0000-0002-0561-6520
Brian K ShoichetDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA 94158, USA. bshoichet@gmail.com laszlo.urban@novartis.com.ORCID 0000-0002-6098-7367
Laszlo UrbanPreclinical Safety, Novartis Institutes for Biomedical Research, Cambridge, MA 02139, USA. bshoichet@gmail.com laszlo.urban@novartis.com.ORCID 0000-0002-1275-0293
University of California, San Francisco · USNovartis (United States) · USNovartis (Switzerland) · CHUniversity of North Carolina at Chapel Hill · USDiscoveRx (United States) · USImperial College London · GBTufts University · US

Funding

Development and Testing of New Computational Methods for Ligand Discovery and MechanismR35GM122481 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Brian K Shoichet · 2017 to 2026
$8.5M
A Web-Based Automatic Virtual Screening SystemR01GM071896 · NIGMS · UNIVERSITY OF TORONTO · PI IRWIN, JOHN J. · 2004 to 2024
$6.0M
UCSF-Stanford Center of Excellence in Regulatory Science and InnovationU01FD004979 · FDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI ALTMAN, RUSS BIAGIO, GIACOMINI, KATHLEEN M · 2014 to 2016
$5.4M
FDA HHS U01 FD004979NIGMS NIH HHS R01 GM071896NIGMS NIH HHS R35 GM122481
6 · The paper itself

Abstract

Excipients, considered "inactive ingredients," are a major component of formulated drugs and play key roles in their pharmacokinetics. Despite their pervasiveness, whether they are active on any targets has not been systematically explored. We computed the likelihood that approved excipients would bind to molecular targets. Testing in vitro revealed 25 excipient activities, ranging from low-nanomolar to high-micromolar concentration. Another 109 activities were identified by testing against clinical safety targets. In cellular models, five excipients had fingerprints predictive of system-level toxicity. Exposures of seven excipients were investigated, and in certain populations, two of these may reach levels of in vitro target potency, including brain and gut exposure of thimerosal and its major metabolite, which had dopamine D3 receptor dissociation constant

Indexed as

Drug CompoundingDrug Evaluation, PreclinicalAnimalsExcipientsHumansMolecular Targeted TherapyExcipients

Identifiers

PMID32703874
PMCPMC7960226
OpenAlexW3044665829

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.